Brutons Tyrosine Kinase (BTK) Inhibitors Pipeline Insight Report 2021 - ResearchAndMarkets.com

The "Brutons Tyrosine Kinase (BTK) Inhibitors - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

This Brutons Tyrosine Kinase (BTK) Inhibitors - Pipeline Insight, 2021 report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Brutons Tyrosine Kinase (BTK) Inhibitors pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

"Brutons Tyrosine Kinase (BTK) Inhibitors - Pipeline Insight, 2021" outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Brutons Tyrosine Kinase (BTK) Inhibitors pipeline landscape is provided which includes the disease overview and Brutons Tyrosine Kinase (BTK) Inhibitors treatment guidelines.

The assessment part of the report embraces, in depth Brutons Tyrosine Kinase (BTK) Inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Brutons Tyrosine Kinase (BTK) Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Brutons Tyrosine Kinase (BTK) Inhibitors drugs?
• How many Brutons Tyrosine Kinase (BTK) Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Brutons Tyrosine Kinase (BTK) Inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Brutons Tyrosine Kinase (BTK) Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Brutons Tyrosine Kinase (BTK) Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• InnoCare Pharma
• BeiGene
• Principia Biopharma
• Carna Biosciences
• Loxo Oncology
• Aptose Biosciences
• Biogen

Key Products

• Orelabrutinib
• Zanubrutinib
• PRN473
• Rilzabrutinib
• AS-0871
• AS-1763
• Pirtobrutinib
• CG-806
• BIIB091

Key Topics Covered:

Introduction

Executive Summary

Brutons Tyrosine Kinase (BTK) Inhibitors: Overview

• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

• Comparative Analysis

Rilzabrutinib: Principia Biopharma

• Product Description
• Research and Development
• Product Development Activities

Mid Stage Products (Phase II)

• Comparative Analysis

Orelabrutinib: InnoCare Pharma

• Product Description
• Research and Development
• Product Development Activities

Early stage products (Phase I)

• Comparative Analysis

PRN473: Principia Biopharma

• Product Description
• Research and Development
• Product Development Activities

Preclinical stage products

• Comparative Analysis

Drug Name: Company Name

• Product Description
• Research and Development
• Product Development Activities

Inactive Products

• Comparative Analysis

Brutons Tyrosine Kinase (BTK) Inhibitors Key Companies

Brutons Tyrosine Kinase (BTK) Inhibitors Key Products

Brutons Tyrosine Kinase (BTK) Inhibitors- Unmet Needs

Brutons Tyrosine Kinase (BTK) Inhibitors- Market Drivers and Barriers

Appendix

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/lupyu2

View source version on businesswire.com: https://www.businesswire.com/news/home/20210917005332/en/

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900